Skip to main content
Premium Trial:

Request an Annual Quote

Provista Adds $2.5M to Series A Financing

NEW YORK (GenomeWeb News) – Provista Diagnostics today said that it has sold an additional $2.5 million of Series A preferred stock, bringing the total amount raised in the round to $7.5 million.

The additional financing was open only to existing shareholders of the firm and was raised through a sale to qualified institutional and individual investors, it said. Earlier this year, the Scottsdale, Ariz.-based developer of blood-based diagnostics for oncology-related diseases raised $5 million in the Series A round.

Proceeds will go toward expansion of its laboratory capabilities, the completion of an ongoing confirmatory clinical trial of Provista's dtectDx-Breast test, formerly called BT Test, a regulatory submission for the test, followed by commercialization of it.

The test detects biomarkers from blood samples. Used in conjunction with mammography, dtect-Breast can support the early detection of breast cancer, the company said.

Funds will also be used for general corporate purposes and the development of pipeline products.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.